Efocipegtrutide
Efocipegtrutide (HM15211, GLP-1/GIP/glucagon triple agonist)
Also known as: HM15211
A triple GLP-1, GIP, and glucagon agonist developed mainly for metabolic liver disease.
Overview
Efocipegtrutide, also known as HM15211, is a long-acting triple agonist of the GLP-1, GIP, and glucagon receptors from Hanmi Pharmaceutical, developed with a particular focus on metabolic dysfunction-associated steatohepatitis (MASH). Like retatrutide it targets all three incretin-related pathways. It is investigational and earlier in development than the leading triple agonist. Update, September 2026: the Phase 2b biopsy-confirmed MASH trial (215 patients) reached primary completion in June 2026; results have not yet been published.
Mechanism of action
Agonizes GLP-1, GIP, and glucagon receptors, combining appetite, insulin, and energy-expenditure effects with liver-directed action.
Key studies & citations
- Human2023
A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed NASH: study design and rationale
Design paper; notes efficacy signals in preclinical NASH models and Phase 1 studies with manageable toxicity.
Contemporary Clinical Trials - Human2026
Study to evaluate efficacy, safety and tolerability of HM15211 (efocipegtrutide) in subjects with biopsy-confirmed NASH
Phase 2, 215 participants, sponsored by Hanmi; status completed with primary completion June 26, 2026.
ClinicalTrials.gov
Frequently asked questions
How does efocipegtrutide compare to retatrutide?
Both are triple GLP-1/GIP/glucagon agonists. Retatrutide is more advanced and obesity-focused, while efocipegtrutide has emphasized metabolic liver disease.